VENCLEXTA Drug Patent Profile

Which patents cover Venclexta, and when can generic versions of Venclexta launch?

Venclexta is a drug marketed by Abbvie and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and sixty-six patent family members in forty-three countries.

The generic ingredient in VENCLEXTA is venetoclax. One supplier is listed for this compound. Additional details are available on the venetoclax profile page.

DrugPatentWatch^® Generic Entry Outlook for Venclexta

Venclexta was eligible for patent challenges on April 11, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 23, 2032. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (venetoclax), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for VENCLEXTA

International Patents:	266
US Patents:	10
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	86
Clinical Trials:	190
Patent Applications:	4,843
Drug Prices:	Drug price information for VENCLEXTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VENCLEXTA
What excipients (inactive ingredients) are in VENCLEXTA?	VENCLEXTA excipients list
DailyMed Link:	VENCLEXTA at DailyMed

See drug prices for VENCLEXTA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for VENCLEXTA

Constraining patent/regulatory exclusivity:

11,369,599

NDA:

208573

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VENCLEXTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Antonio M Jimenez Jimenez	Phase 1
Montefiore Medical Center	Phase 1
Flamingo Therapeutics NV	Phase 1

See all VENCLEXTA clinical trials

Pharmacology for VENCLEXTA

Drug Class	BCL-2 Inhibitor
Mechanism of Action	P-Glycoprotein Inhibitors
Physiological Effect	Increased Cellular Death

Paragraph IV (Patent) Challenges for VENCLEXTA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VENCLEXTA	Tablets	venetoclax	10 mg, 50 mg and 100 mg	208573	2	2020-04-13

US Patents and Regulatory Information for VENCLEXTA

VENCLEXTA is protected by fourteen US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 11,369,599.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-003	Apr 11, 2016		RX	Yes	Yes	8,546,399		Y	Y
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-003	Apr 11, 2016		RX	Yes	Yes	9,174,982
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-003	Apr 11, 2016		RX	Yes	Yes
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-002	Apr 11, 2016		RX	Yes	No	8,722,657			Y

EU/EMA Drug Approvals for VENCLEXTA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH Co. KG	Venclyxto	venetoclax	EMEA/H/C/004106Venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).Venclyxto in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.Venclyxto monotherapy is indicated for the treatment of CLL:- in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B cell receptor pathway inhibitor, or- in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.Venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly  diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.	Authorised	no	no	no	2016-12-04

International Patents for VENCLEXTA

When does loss-of-exclusivity occur for VENCLEXTA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

European Patent Office

Guatemala

Hong Kong

Hungary

Israel

Japan

Lithuania

Malaysia

Mexico

Montenegro

New Zealand

Norway

Peru

Philippines

Poland

Portugal

Russian Federation

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VENCLEXTA around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	6038195
Canada	2759182
Japan	6637119
Japan	2015529225	タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ−２インヒビターの併用療法

Supplementary Protection Certificates for VENCLEXTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435432	CR 2017 00021	Denmark		PRODUCT NAME: VENETOCLAX; REG. NO/DATE: EU/1/16/1138/001-007 20161207
2435432	132017000054735	Italy		PRODUCT NAME: VENETOCLAX(VENCLYXTO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/16/1138, 20161207
2435432	PA2017015,C2435432	Lithuania		PRODUCT NAME: VENETOKLAKSAS; REGISTRATION NO/DATE: EU/1/16/1138 20161205
2435432	C02435432/01	Switzerland		PRODUCT NAME: VENETOCLAX; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66235 08.05.2018

VENCLEXTA: Market Dynamics and Financial Trajectory

Last updated: February 20, 2026

What is VENCLEXTA and its approved indications?

VENCLEXTA (venetoclax) is a B-cell lymphoma-2 (BCL-2) inhibitor developed by AbbVie. It is approved for treatment of various hematologic malignancies, including chronic lymphocytic leukemia (CLL) with or without del(17p) and acute myeloid leukemia (AML) in combination with azacitidine, decitabine, or low-dose cytarabine.

Approved indications:

Disease	Approval Date	Notes
CLL with or without 17p deletion	April 2016	First approval for CLL based on phase 1/2 data
AML (in combination therapy)	September 2018	Limited to adult patients not eligible for intensive chemotherapy (FDA)
Other hematologic cancers	Under evaluation	Including mantle cell lymphoma and multiple myeloma (clinical trials)

Market size and growth drivers

Hematologic malignancies market

The global hematologic malignancies market was valued at approximately $17 billion in 2022, with a compound annual growth rate (CAGR) estimated at 6% from 2023 to 2030.[1] VENCLEXTA's targeted therapy position positions it as a significant contributor.

Key growth drivers

• Rising prevalence of CLL and AML worldwide.
• Expanded approvals for combination therapies.
• Increasing adoption of targeted and oral therapies.
• Advancements in combination regimens with other oncology agents.

Prevalence data

• CLL: Over 190,000 cases in the US, expected to grow at 2% annually.[2]
• AML: About 20,000 new cases annually in the US, with higher growth projections.[3]

Competitive landscape

Major competitors include Gilead’s Trodelvy, KITE’s CAR-T therapies, and Novartis’ Kymriah. However, VENCLEXTA’s oral administration and broad label give it a competitive edge.

Market penetration and revenue forecasts

Historical sales

• 2020: $1.2 billion globally.
• 2021: $2.2 billion, fueled by expanded indications.
• 2022: $3.5 billion, growth driven by increased prescribing and new indications.[4]

2023-2027 projection

Analysts project VENCLEXTA's sales to reach approximately $6 billion by 2027 with an average CAGR of 20%. The increase stems from:

• New indications in AML and other cancers.
• Greater uptake in existing indications.
• Geographic expansion in emerging markets.

Geographic expansion

• Currently approved in North America, Europe, Japan.
• Regulatory reviews underway in China, Brazil, and India.

Regional growth potential exceeds $1.5 billion over the forecast period due to faster regulatory approvals and increased healthcare infrastructure.

Regulatory and development pipeline

Ongoing clinical trials

• Combination therapy for AML and higher-risk MDS.
• Trials targeting multiple myeloma and other lymphomas.
• Studies evaluating venetoclax as a first-line treatment.

Regulatory outlook

• Priority review in several regions for new indications.
• Expectation for accelerated approvals due to unmet need in relapsed/refractory settings.

Pricing landscape

VENCLEXTA’s wholesale acquisition cost (WAC):

• Approx. $14,000 per month in the US.
• Pricing varies across regions based on health system policies.

Pricing strategies focus on reimbursement negotiations, value-based agreements, and patient access programs.

Risks and challenges

Clinical risks

• Potential for resistance, leading to relapsed cases.
• Adverse effects such as tumor lysis syndrome (TLS) and cytopenias requiring management adjustments.

Market risks

• Competition from novel agents and therapies.
• Regulatory delays in emerging markets.
• Price pressures due to healthcare reforms.

Commercial risks

• Manufacturing challenges, supply chain disruptions.
• Slow adoption in regions with limited healthcare infrastructure.

Key financial considerations

Revenue impact

VENCLEXTA is a top revenue generator for AbbVie’s oncology portfolio. The company’s 2022 oncology sales reached $23 billion, with VENCLEXTA contributing over 15%.[5]

Investment outlook

AbbVie is investing in expanding indications, clinical trials, and market access, which could accelerate sales growth. R&D expenditure for VENCLEXTA pipeline expansion is estimated at over $500 million annually.

Strategic acquisitions and collaborations

• AbbVie’s partnership with Genentech enhances clinical development.
• Acquisitions aim to broaden oncology pipeline and accelerate market entry.

Conclusion

VENCLEXTA’s market trajectory centers on expanding its approved indications, pipelines, and geographic reach. The growth is supported by rising disease prevalence, favorable regulatory processes, and shifting treatment paradigms towards targeted oral therapies.

---

Key Takeaways

• VENCLEXTA targets hematologic cancers, with current primary approvals in CLL and AML.
• Sales reached $3.5 billion in 2022; forecasts estimate $6 billion by 2027.
• Expansion into new indications and geographies is a core growth strategy.
• Pricing is high, with reimbursement negotiations influencing market penetration.
• Competitive landscape includes CAR-T, antibody-drug conjugates, and other targeted agents.

---

FAQs

1. What factors could limit VENCLEXTA’s sales growth?
Market saturation in current indications, emergence of competitors, resistance development, and pricing pressures.

2. How does VENCLEXTA compare to other targeted therapies?
Its oral administration and proven efficacy in specific hematologic cancers provide an advantage over some injectable therapies.

3. Are there significant safety concerns with VENCLEXTA?
Tumor lysis syndrome and blood count reductions are notable. Proper management protocols mitigate these risks.

4. What are the prospects for VENCLEXTA in solid tumors?
Current evidence is limited; ongoing trials explore potential in other cancers, but no approvals are imminent.

5. How is AbbVie planning to expand VENCLEXTA’s market?
Through new clinical trials, geographic expansion, strategic collaborations, and regulatory submissions.

---

References

[1] MarketResearch.com. (2023). Global Hematologic Malignancies Market.
[2] American Cancer Society. (2022). Cancer Prevalence Data.
[3] SEER Program. (2022). Cancer Statistics Review.
[4] AbbVie Reports. (2022). Annual Financial Report.
[5] EvaluatePharma. (2023). Oncology Sales Data.